<DOC>
	<DOCNO>NCT00119678</DOCNO>
	<brief_summary>The purpose clinical research study learn whether Abatacept treat prevent lupus flare ; specifically , patient active lupus flare least one three organ system : skin ( discoid lesion ) ; inflammation line heart ( pericarditis ) , inflammation lining lung ( pleuritis/pleurisy ) ; inflammation 4 joint ( arthritis ) . All participant receive prednisone prednisone-equivalent treatment combination study medication . The safety treatment also study .</brief_summary>
	<brief_title>Abatacept Treatment Prevention Active Systemic Lupus Erythematosus ( SLE ) Flares Combination With Prednisone</brief_title>
	<detailed_description />
	<mesh_term>Lupus Erythematosus , Systemic</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Abatacept</mesh_term>
	<criteria>participant must diagnose SLE experience active lupus flare least one three organ system : skin ( discoid lesion ) , inflammation line heart ( pericarditis ) , inflammation lining lung ( pleuritis/pleurisy ) ; inflammation 4 joint within 14 day screen visit ( arthritis ) Stable dose prednisone ( &lt; 30mg ) least one month participant experience active lupus flare kidney central nervous system Treatment stable dose azathioprine , mycophenolate mofetil , hydroxychloroquine , chloroquine , methotrexate less three month prior study participant active viral bacterial infection participant autoimmune disease main diagnosis Prior treatment rituximab</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2014</verification_date>
	<keyword>SLE</keyword>
</DOC>